Cidara Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
RA Capital Management reports the completion of the tender offer and merger of Cidara Therapeutics, resulting in its delisting from Nasdaq and RA Capital's full divestment.
Merck Sharp & Dohme LLC's subsidiary, Caymus Purchaser, Inc., will launch a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per common share and $15,505.00 per Series A preferred share.
RA Capital Management and its affiliates reported a dilution of their beneficial ownership in Cidara Therapeutics, Inc. to 10.7% due to new share issuances by the company.
RA Capital Management and its affiliates report a 13.3% beneficial ownership in Cidara Therapeutics, Inc., holding over 3.3 million common shares.
RA Capital Management and its affiliates have significantly increased their beneficial ownership in Cidara Therapeutics, Inc. to 15.8% of outstanding common stock after investing nearly $100 million in a recent public offering.